Early hypophosphataemia and refeeding syndrome in extremely low birthweight babies and outcomes to 2 years of age: secondary cohort analysis from the ProVIDe trial
- 9 August 2024
- journal article
- research article
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 110 (2) , 157-164
Abstract
Objective: To investigate in extremely low birthweight (ELBW; -1 ) and hypophosphataemia in the first week and death or neurodisability at 2 years’ corrected age (CA). Design: Secondary cohort analysis of the ProVIDe trial participants with serum biochemistry within 7 days of birth. At 2 years’ CA, neurodisability was assessed by Bayley Scales of Infant Development Edition III and neurological examination. Associations between neurodisability and other variables were analysed using t-tests and logistic regression adjusted for sex and smallness-for-gestational age. Setting: Six tertiary neonatal intensive care units (NICUs) in New Zealand. Participants: 352 ELBW babies born between 29 April 2014 and 30 October 2018. Main outcome measure: Death or neurodisability at 2 years’ CA. Results: Fifty-nine babies died, two after discharge from the NICU. Of the 336 babies who survived to 2 years’ CA, 277 had neurodevelopmental assessment and 107 (39%) had a neurodisability. Death or neurodisability was more likely in babies who had refeeding syndrome (aOR 1.96 (95% CI 1.09 to 3.53), p=0.02) and in babies who had hypophosphataemia (aOR 1.74 (95% CI 1.09 to 2.79), p=0.02). Hypophosphataemia was associated with increased risk of death (aOR 2.07 (95% CI 1.09 to 3.95), p=0.03)) and severe hypophosphataemia (-1 ) with increased risk of death (aOR 2.67 (95% CI 1.41 to 5.00), p=0.002) and neurodisability (aOR 2.31 (95% CI 1.22 to 4.35), p=0.01). Conclusions: In ELBW babies, refeeding syndrome and hypophosphataemia in the first week are associated with death or neurodisability. Until optimal phosphate requirements are determined through further research, monitoring for hypophosphataemia and mitigation strategies are indicated. Trial registration number: ACTRN12612001084875Keywords
Funding Information
- Health Research Council of New Zealand (14/174)
- Auckland DHB Charitable Trust (A+5854)
- Nurture Foundation for Reproductive Research (A+5854)
- Lotteries Grants Board (3705291)
- Cure Kids (3550, 3580)
- Gravida: National Centre for Growth and Development (SCH 14/15)
This publication has 36 references indexed in Scilit:
- Neurodevelopmental outcomes of premature infants with intraventricular hemorrhage across a lifespanSeminars in Perinatology, 2022
- Neurodevelopmental outcomes of infants with bronchopulmonary dysplasiaPediatric Pulmonology, 2021
- Neonatal Refeeding Syndrome and Clinical Outcome in Extremely Low‐Birth‐Weight Babies: Secondary Cohort Analysis From the ProVIDe TrialJournal of Parenteral and Enteral Nutrition, 2020
- Neurodevelopmental outcomes of extremely preterm infants in southern China: A multicenter studyEarly Human Development, 2019
- ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Calcium, phosphorus and magnesiumClinical Nutrition, 2018
- Safety and Efficacy of Early Parenteral Lipid and High-Dose Amino Acid Administration to Very Low Birth Weight InfantsThe Journal of Pediatrics, 2013
- Enhanced feeding in very-low-birth-weight infants may cause electrolyte disturbances and septicemia – A randomized, controlled trialClinical Nutrition, 2013
- Refeeding syndrome in very-low-birth-weight intrauterine growth-restricted neonatesJournal of Perinatology, 2013
- Calcium and Phosphorus Homeostasis: Pathophysiology2012
- Estimation of fetal weight: reference range at 20–36 weeks' gestation and comparison with actual birth‐weight reference rangeUltrasound in Obstetrics & Gynecology, 2007